keyword
MENU ▼
Read by QxMD icon Read
search

interim Pet hodgkin

keyword
https://www.readbyqxmd.com/read/28254870/interim-pet-in-hodgkin-lymphoma-is-it-so-useless
#1
Michel A Meignan, Anne-Segolene Cottereau, Benedicte Deau, Salim Kanoun, Alina Berriolo Riedinger, Olivier Casasnovas
No abstract text is available yet for this article.
March 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28237632/predicting-outcomes-after-a-positive-interim-fdg-pet-scan-in-advanced-hodgkin-s-lymphoma
#2
Michael Crump
No abstract text is available yet for this article.
February 22, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#3
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
February 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28185527/use-of-fluorodeoxyglucose-positron-emission-tomography-for-diagnosis-of-bleomycin-induced-pneumonitis-in-hodgkin-lymphoma
#4
Okan Falay, Erman Öztürk, Yasemin Bölükbaşı, Terman Gümüş, Serdar Örnek, Murat Özbalak, Mustafa Çetiner, Onur Demirkol, Burhan Ferhanoğlu
Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity. Early diagnosis of bleomycin-induced pneumonitis is crucial to prevent irreversible damage. Pulmonary function tests are unreliable for identifying risk of bleomycin toxicity. Fluorodeoxyglucose PET/CT scanning can reveal inflammation secondary to pneumonitis but is not sufficiently specific for diagnosis. We retrospectively analyzed scans from 77 patients with Hodgkin lymphoma (median age 41 years, mean bleomycin dose 134 mg) to evaluate bleomycin-induced pneumonitis...
May 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28151888/pediatric-hodgkin-lymphoma-predictive-value-of-interim-18f-fdg-pet-ct-in-therapy-response-assessment
#5
Cristina Ferrari, Artor Niccoli Asabella, Nunzio Merenda, Corinna Altini, Margherita Fanelli, Paola Muggeo, Francesco De Leonardis, Teresa Perillo, Nicola Santoro, Giuseppe Rubini
We investigated the prognostic value of interim F-FDG PET/CT (PET-2) in pediatric Hodgkin lymphoma (pHL), evaluating both visual and semiquantitative analysis.Thirty pHL patients (age ≤16) underwent serial F-FDG PET/CT: at baseline (PET-0), after 2 cycles of chemotherapy (PET-2) and at the end of first-line chemotherapy (PET-T). PET response assessment was carried out visually according to the Deauville Score (DS), as well as semiquantitatively by using the semiquantitative parameters reduction from PET-0 to PET-2 (ΔΣSUVmax0-2, ΔΣSUVmean0-2)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28132716/-18-f-fdg-pet-mri-in-lymphoma-patients
#6
Eva Ferdová, Jiří Ferda, Jan Baxa
The introduction of hybrid PET/MRI imaging using integrated systems into clinical practice has opened up the possibility of reducing the radiation dose from hybrid imaging by eliminating the contribution from computed tomography. Studies comparing the possibilities of PET/CT and PET/MRI imaging demonstrated it is possible to use the advantages of the high contrast resolution of magnetic resonance for soft tissue and bone marrow along with PET records in a quality comparable to PET/CT imaging. The significant feature for PET imaging in Hodgkińs lymphoma is that it is a tissue with high levels of radiopharmaceutical accumulation, which decreases proportionally after successful therapeutic effect, the effect of therapy is assessed using Deauville score system on interim examinations...
January 23, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28126883/prognostic-value-of-bone-marrow-tracer-uptake-pattern-in-baseline-pet-scan-in-hodgkin-lymphoma-results-from-an-international-collaborative-study
#7
Colette Zwarthoed, Tarec Cristoffer El-Galaly, Maria Canepari, Matthieu John Ouvrier, Julien Viotti, Marc Ettaiche, Simonetta Viviani, Luigi Rigacci, Livio Trentin, Chiara Rusconi, Stefano Luminari, Maria Cantonetti, Silvia Bolis, Anna Borra, Jacques Darcourt, Flavia Salvi, Edyta Subocz, Joanna Tajer, Waldemar Kulikowski, Bogdan Malkowski, Jan Maciej Zaucha, Andrea Gallamini
RATIONALE: Positron Emission Tomography/Computed Tomography (PET/CT)-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analysed the clinico-pathological correlations and prognostic meaning of different patterns of bone marrow (BM)-Fluorodeoxyglucose (FDG)-uptake in HL. PATIENTS AND METHODS: 180 newly diagnosed early unfavourable and advanced stage HL patients, all scanned at baseline and after 2 Adriamycin-Bleomycin-Vinblastine-Dacarbazine (ABVD) courses with FDG-PET, enrolled in two International studies aimed at assessing the role of interim PET scan in HL, were retrospectively included...
January 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28117395/utility-of-baseline-interim-and-end-of-treatment-18-f-fdg-pet-ct-in-extranodal-natural-killer-t-cell-lymphoma-patients-treated-with-l-asparaginase-pegaspargase
#8
Yu Chang, Xiaorui Fu, Zhenchang Sun, Xinli Xie, Ruihua Wang, Zhaoming Li, Xudong Zhang, Guangyao Sheng, Mingzhi Zhang
Positron emission tomography-computed tomography (PET/CT) is widely used for initial staging and monitoring treatment responses in Hodgkin and diffuse large B-cell lymphoma. However, its prognostic value in extranodal natural killer (NK)/T-cell lymphoma (ENKL) remains unclear. Here, we conducted a retrospective study to determine the impact of PET/CT in ENKL. Fifty-two patients newly diagnosed with ENKL were enrolled. Baseline maximum standardized uptake values (SUVmax), whole-body metabolic tumor volume (WBMTV) and whole-body total lesion glycolysis (WBTLG) were recorded...
January 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28090627/fdg-pet-for-early-response-assessment-in-lymphomas-part-2-diffuse-large-b-cell-lymphoma-use-of-quantitative-pet-evaluation
#9
REVIEW
Bruce D Cheson, Lale Kostakoglu
In Part 1, we reviewed the role of interim positron emission tomography (PET)/CT scans in Hodgkin lymphoma. In advanced Hodgkin lymphoma, interim PET is a useful prognostic tool that can be used to implement risk-adapted therapy with potential benefits for both patients who have negative interim scans and those whose scans are positive. Interim PET/CT has not shown as encouraging results in diffuse large B-cell lymphoma (DLBCL), with the exception of germinal center B-cell DLBCL. Thus, quantitative methods of interpreting interim PET scans have been pursued in an effort to improve their predictive value...
January 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28090622/fdg-pet-for-early-response-assessment-in-lymphomas-part-1-hodgkin-lymphoma
#10
REVIEW
Bruce D Cheson, Lale Kostakoglu
Interim positron emission tomography (PET)/CT has shown encouraging results when used as a prognostic tool early in the course of treatment of advanced Hodgkin lymphoma, allowing for a reduction in treatment for patients with favorable characteristics, while suggesting a benefit from changing therapy for those with a positive scan. For patients with limited disease, a negative scan allows for a decrease in treatment; however, the benefits for those patients whose scans are positive are less certain. Here we critically analyze the role of PET/CT in the early assessment of Hodgkin lymphoma...
January 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27997427/cat-scratch-disease-a-pitfall-for-lymphoma-evaluation-by-fdg-pet-ct
#11
Julien Dubreuil, Arthur Dony, Gilles Salles, Alexandra Traverse-Glehen, Francesco Giammarile, Andrea Skanjeti
FDG-PET/CT is a standard of care in staging and response assessment of Hodgkin lymphoma. Hence, it is important to recognize pitfalls owing to the potential therapeutic impact. We report a case of a 29-year-old woman affected by stage III bulky Hodgkin lymphoma. The interim FDG-PET/CT showed a complete metabolic response. After three new cycles of chemotherapy, the patient showed fever and lymphadenopathy at clinic examination, PET/CT revealed several FDG uptakes at lymph nodes in inguinal and iliac region...
February 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27932560/reply-neither-post-treatment-pet-ct-nor-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma
#12
Sainath Bhethanabhotla, Sameer Bakhshi
No abstract text is available yet for this article.
December 8, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27913497/response-adapted-frontline-therapy-for-hodgkin-lymphoma-are-we-there-yet
#13
Peter W M Johnson
Treating Hodgkin lymphoma by using chemotherapy with or without radiotherapy is highly successful, with substantially fewer deaths from lymphoma than from other causes in recent studies of both early-stage and advanced-stage disease. Long-term toxicity is a major consideration in this context, and recent trials have used functional imaging with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography early in the course of treatment (interim PET) to assess response and modulate subsequent therapy. In early-stage disease, this has allowed omission of consolidation radiotherapy after a good response to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy, and trials have shown that this can be done without detriment to overall survival, despite a small increase in rates of recurrence of ∼5%...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27879369/response-assessment-criteria-and-their-applications-in-lymphoma-part-2
#14
REVIEW
Mateen C Moghbel, Erik Mittra, Andrea Gallamini, Ryan Niederkohr, Delphine L Chen, Katherine Zukotynski, Helen Nadel, Lale Kostakoglu
Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin and non-Hodgkin lymphoma. This review article seeks to aid clinical decision making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pretransplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments...
January 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27867987/modifying-therapy-in-patients-with-advanced-hodgkin-s-lymphoma-by-integrating-early-metabolic-response-by-interim-pet-ct
#15
EDITORIAL
Ulrike Bacher, Mascha Binder
No abstract text is available yet for this article.
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27795508/update-on-the-use-of-fdg-pet-ct-in-malignant-lymphoma
#16
Takashi Terauchi
This article aims to explain the current status of FDG-PET/CT in malignant lymphoma management by reviewing the new recommendations for evaluation, staging, and response assessment in patients with malignant lymphoma, published as the Lugano Classification in 2014. FDG-PET/CT was formally incorporated into standard staging for FDG-avid lymphoma in this new classification. Nearly all subtypes of malignant lymphoma are FDG-avid. In staging, the increased FDG uptake compatible with lymphoma is considered to represent involvement of lymphoma, regardless of size, and the FDG-avid lesion is potentially a good biopsy target...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/27776647/proportion-of-false-positive-lesions-at-interim-and-end-of-treatment-fdg-pet-in-lymphoma-as-determined-by-histology-systematic-review-and-meta-analysis
#17
REVIEW
Hugo J A Adams, Thomas C Kwee
PURPOSE: To systematically review and meta-analyze the proportion of false-positive lesions at interim and end-of-treatment (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in lymphoma using biopsy as reference standard. MATERIALS AND METHODS: Medline was searched for original studies. Methodological quality of included studies was evaluated, and results were meta-analytically summarized using random effects (in case of interstudy heterogeneity [I(2)≤50%]) or fixed effects (in case of no interstudy heterogeneity [I(2)>50%])...
November 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27754902/post-treatment-pet-ct-rather-than-interim-pet-ct-using-deauville-criteria-predicts-outcome-in-pediatric-hodgkin-lymphoma-a-prospective-study-comparing-pet-ct-versus-conventional-imaging
#18
Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27693134/interim-pet-scans-in-diffuse-large-b-cell-lymphoma-is-it-ready-for-prime-time
#19
REVIEW
Maital Bolshinsky, Chadi Nabhan
Prognostication of patients with diffuse large B-cell lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (I-PET) in Hodgkin lymphoma, several retrospective and prospective studies are attempting to assess the value of I-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of I-PET scanning in this disease...
December 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27692305/the-combined-role-of-biomarkers-and-interim-pet-scan-in-prediction-of-treatment-outcome-in-classical-hodgkin-s-lymphoma-a-retrospective-european-multicentre-cohort-study
#20
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
keyword
keyword
118763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"